Abstract 13727: Effects of Ziltivekimab (ZILTI), a Novel Anti-Interleukin-6 Monoclonal Antibody, on Markers of Inflammation and Cardiovascular Risk in Patients With Chronic Kidney Disease on Hemodialysis
Circulation（2019）
摘要
Introduction: Levels of the inflammatory cytokine IL-6 and its associated biomarker CRP, the production of which is predominantly stimulated by IL-6, are strongly correlated with CV outcomes in CKD...
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要